Amgen Hits Mylan With Patent Suit Over Neulasta Biosimilar
Mylan Inc. infringed two of Amgen Inc.'s patents when seeking to get its biosimilar of Amgen's blockbuster anti-infection medicine Neulasta on the market before the patents expired, the biologic maker told...To view the full article, register now.
Already a subscriber? Click here to view full article